Insurance companies and drugmakers are wrestling with the high cost of making and administering biologic drugs, says Avery Johnson on the Wall Street Journal's Health blog. These drugs can cost as much as $1.5 million a year, and patients and prescription plan payers are having a hard time affording them. On the other hand, Johnson adds, some of these drugs have "dramatic" results, sending sometimes-fatal diseases into remission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.